Safety of canagliflozin in patients with type 2 diabetes

Current Drug Safety

Volumn 9, Issue 2, 2014, Pages 127-132

  Mikhail, Nasser ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Canagliflozin; Dapagliflozin; Genital infection; Safety; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIMEPIRIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; GLUCOSIDE; LIPID; THIOPHENE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEHYDRATION; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; KIDNEY FUNCTION; MICTURITION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE VOLUME; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPERKALEMIA; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; THIOPHENES; URINARY TRACT INFECTIONS; URINATION;

EID: 84904723621     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886309666140120100255     Document Type: Article

References (20)

1. Wright EM, Loo DDF, Hirayama BA, Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-94.
2. Taylor SR, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33: 984-99.
3. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabetic Med 2010; 27: 136-42.
4. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-10.
5. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-73.
6. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54(12): 3427-34.
7. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013; 36(8): 2154-61.
8. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately with diet and exercise. Diabetes Obes Metabol 2013; 15: 372-82.
9. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes: a randomized trial. Hosp Pract 2013; 41: 72-84.
10. Invokana (canagliflozin). Prescribing information. Janssen Ortho, LLC. Gurabo, PR 00778, March 2013.
11. European Medicines Agency. Forxiga (Dapagliflozin). Accessed at: http://ec. europa. eu/health/doccuments/communityregister/2012/201 21112124487/anx_124487_en pdf on September 29, 2013.
12. Haring H, Merker L, Seewaldi-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-4404.
13. Schemthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
14. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-50.
15. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 1173-78.
16. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteruria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012; 28: 1167-71.
17. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as addon to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
18. Neal B, Perkovic V, de Zccuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013; 166: 217-23.
19. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodiumglucose cotransporter 2 inhibtors for type 2 diabetes. A systemic review and meta-analyis. Ann Int Med 2013; 159: 262-74.
20. Ptaszynska A, Hardy E, Johnsson E, et al. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 2013; 125: 181-9.